AbbVie Inc (ABBV)vsWarby Parker Inc (WRBY)
ABBV
AbbVie Inc
$227.23
-2.69%
HEALTHCARE · Cap: $380.57B
WRBY
Warby Parker Inc
$22.72
-5.80%
HEALTHCARE · Cap: $3.04B
Smart Verdict
WallStSmart Research — data-driven comparison
AbbVie Inc generates 6954% more annual revenue ($62.82B vs $890.57M). ABBV leads profitability with a 5.8% profit margin vs 0.1%. ABBV trades at a lower P/E of 105.1x. ABBV earns a higher WallStSmart Score of 63/100 (C+).
ABBV
Buy63
out of 100
Grade: C+
WRBY
Avoid31
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-55.6%
Fair Value
$146.00
Current Price
$227.23
$81.23 premium
Margin of Safety
-50.4%
Fair Value
$14.62
Current Price
$22.72
$8.10 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 62 in profit
Strong operational efficiency at 32.2%
Conservative balance sheet, low leverage
Growing faster than its price suggests
Generating 3.6B in free cash flow
No standout strengths identified
Areas to Watch
5.8% margin — thin
Premium valuation, high expectations priced in
Earnings declined 46.2%
Distress zone — elevated risk
ROE of 0.4% — below average capital efficiency
0.1% margin — thin
Operating margin of 0.9%
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : ABBV
The strongest argument for ABBV centers on Market Cap, Return on Equity, Operating Margin. Revenue growth of 12.4% demonstrates continued momentum. PEG of 0.59 suggests the stock is reasonably priced for its growth.
Bull Case : WRBY
WRBY has a balanced fundamental profile.
Bear Case : ABBV
The primary concerns for ABBV are Profit Margin, P/E Ratio, EPS Growth. A P/E of 105.1x leaves little room for execution misses.
Bear Case : WRBY
The primary concerns for WRBY are Return on Equity, Profit Margin, Operating Margin. A P/E of 2479.0x leaves little room for execution misses. Thin 0.1% margins leave little buffer for downturns.
Key Dynamics to Monitor
WRBY carries more volatility with a beta of 1.96 — expect wider price swings.
ABBV is growing revenue faster at 12.4% — sustainability is the question.
ABBV generates stronger free cash flow (3.6B), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
ABBV scores higher overall (63/100 vs 31/100) and 12.4% revenue growth. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AbbVie Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.
Warby Parker Inc
HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA
Warby Parker Inc. (WRBY) is a trendsetting leader in the direct-to-consumer eyewear market, established in 2010 with the mission to revolutionize the way consumers purchase eyewear through a seamless blend of online shopping and an expanding number of retail stores. The company is renowned for its stylish, affordable prescription glasses and sunglasses, appealing to a broad range of customers. Warby Parker's socially conscious business model, epitomized by its "Buy a Pair, Give a Pair" initiative, reflects a commitment to social responsibility by providing eyewear to those in need. With a robust brand reputation and a dedication to innovative marketing strategies, Warby Parker is well-positioned for ongoing growth and success in a competitive landscape.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?